Skip to main content

Market Access for Medical Technologies in Germany

A brief overview of key market access pathways and challenges for medical devices, in-vitro diagnostic tests in Germany

dfv

Key Topics

There are three key themes describing market access for medical technologies in Germany:

  • Reimbursement: payment mechanism via DRG system, add-on reimbursement via ZE in hospital settings; payment via EBM catalog in out-patient settings
  • Funding: coverage decisions within statutory health insurance by the Federal Joint Committee (G-BA)
  • Health technology assessment: assessments by IQWiG in relation to the creation of out-patient reimbursement codes

Germany has a number of innovative payment schemes for medical technologies. 

dghj

Reimbursement

Reimbursements for hospital procedures are made solely via a German-diagnosis-related group (G-DRG) system. All cases of hospitalization with at least one overnight stay are reimbursed via DRG. Day cases and out-patient care are completely separate from hospital care provisions and are reimbursed via a fee-for-service model (EBM catalog within the statutory health insurance).

The DRG system has the following components:

Diagnosis-related groups

  • DRGs are determined by the combination of a procedure code (OPS) and a diagnosis code (ICD-10-GM). OPS nomenclature is maintained by the BfArM Cologne Office (ex DIMDI) and released annually
  • Most DRGs have a national tariff, which is determined by the administrator of the DRG system, the Institute for the Hospital Remuneration System (InEK)

Add-on reimbursement (Zusatzentgelt, ZE)

  • Add-on reimbursement is provided for expensive devices, procedures, and drugs
  • ZE might or might not have a national tariff

The G-DRG system is approved annually.

Innovation funding (NUB) is not formally part of the DRG system. NUB is granted by InEK for a period of less than a year based on the review of applications made by hospitals. Approved status (status 1) gives hospitals the opportunity to negotiate additional reimbursement with sickness funds. However, it does not guarantee reimbursement, as sickness funds may question the sufficiency of the evidence provided and decide not to pay for the technology.

In out-patient settings, procedures are reimbursed via a fee-for-service mechanism via the EBM Catalog. There are specifics of reimbursement for surgical procedures in day case settings. 

gfhgjh

Funding

From 2016, the national policy-maker, the Federal Joint Committee (Der Gemeinsame Bundesausschuss, G-BA), may initiate a “benefit assessment” procedure for applications dealing with devices from high-risk classes (IIb and III). This would ensure that the level of evidence is sufficient for the device’s use in the German statutory health insurance system. 

dfghjk

Health Technology Assessment

HTA is almost exclusively limited to assessments by IQWiG in relation to the creation of out-patient reimbursement codes.

111

Specifics for IVD Tests

In-vitro diagnostic tests are reimbursed using a fee-for-service mechanism via the EBM Catalog in out-patient settings.

MTRC has experience with more than 400 projects in Germany

News and Insights

Bundestag Adopts Amendments to Abolish Hybrid DRGs from 2028 in Germany

On October 15, 2026, the German Federal Ministry of Health (BMG) announced that the Bundestag had adopted amendments to the Statutory Health Insurance (SHI) Contribution Rate Stabilization Act. A key change concerns the restructuring of reimbursement for outpatient and short-stay inpatient procedures, with Hybrid DRGs set to be abolished from 2028. From 2027, procedures without an overnight stay will transition to regular outpatient reimbursement, while procedures involving an overnight stay will remain under Hybrid DRG tariffs until new short-stay case-based payments are introduced.

Germany Proposes Abolishing Hybrid DRGs and Restructuring Short-Stay Reimbursement from 2028

On 8 October 2026, the National Association of Statutory Health Insurance Physicians (KBV) reported proposed legislative amendments that could fundamentally change reimbursement for short-stay and outpatient procedures in Germany. Under the proposal, the existing Hybrid DRG mechanism would be abolished from 1 January 2028, with short-stay hospital cases reimbursed through a new system of flat-rate payments. Procedures without an overnight stay would transition to reimbursement under the EBM fee schedule from 2027.

The revised EBM catalog for the fourth quarter of 2026 was published in Germany

On October 1, 2026, the revised EBM (German Uniform Evaluation Standard) catalog for the fourth quarter of 2026 came into force. The EBM catalog is used to reimburse day case and outpatient services under the fee-for-service model. The main changes introduced concern updates to the contents (service legends and preambles of several EBM subchapters) and the introduction of several new EBM codes.

Get in Touch

Contact us to discuss your needs and learn about our services